News on the front of diabetes have revealed the remarkable results of multifactorial treatment of type 2 diabetes on morbidity and mortality. Micro and macro-angiopathic complications have markedly decreased during the last 20 years. However, intervention trials on glycemic control alone show a slight or no benefit on cardiovascular complications or mortality when intensive treatment aims at HbA1c below 7.0-7.5%. Life adaption remains a critical part of diabetes treatment to decrease cardiovascular risk. Recent knowledge on nutrition and meal frequency has taught us to distrust old dogmas.